Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CERo Therapeutics Holdings ( (CERO) ) has shared an announcement.
CERo Therapeutics Holdings, Inc. has completed multiple closings of its Series D convertible preferred stock sale, raising significant capital in 2025. The transactions, conducted in private placements, reflect strategic fundraising efforts to support the company’s operations and growth, leveraging exemptions under securities laws to engage accredited investors.
The most recent analyst rating on (CERO) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is involved in private placement offerings of convertible preferred stock to institutional investors.
Average Trading Volume: 1,193,594
Technical Sentiment Signal: Sell
Current Market Cap: $4.32M
Learn more about CERO stock on TipRanks’ Stock Analysis page.